Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
31 Março 2022 - 5:26PM
Edgar (US Regulatory)
PROSPECTUS SUPPLEMENT
(To Prospectus dated September 2, 2020) |
Filed pursuant to Rule 424(b)(5)
Registration Statement No. 333-240366 |
Idera Pharmaceuticals, Inc.
Up to $10,431,194
Common Stock
We previously entered into a certain equity distribution
agreement, or the Equity Distribution Agreement, dated November 26, 2018, with JMP Securities LLC, relating to
the sale of up to $50,000,000 shares of our common stock, $0.001 par value per share, or the Common Stock. Pursuant to the Equity Distribution
Agreement, prior to the date of this prospectus supplement, we have sold 9,258,770 shares of Common Stock, resulting in gross proceeds
of $30,479,055, which leaves $19,520,945 of Common Stock available under the Equity Distribution Agreement. This prospectus supplement
should be read in conjunction with the Prospectus dated September 2, 2020, or the Prospectus, and is qualified by reference thereto,
except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement
is not complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements
thereto.
We are now subject to General Instruction I.B.6
of Form S-3, which limits the amounts that we may sell under the registration statement of which this prospectus supplement and the
Prospectus form a part. The aggregate market value of our common stock held by non-affiliates pursuant to General Instruction I.B.6 of
Form S-3 is $31,293,582, which was calculated based on 52,155,970 shares of our outstanding common stock held by non-affiliates on
March 14, 2022 at a price of $0.60 per share, the closing price of our common stock on February 1, 2022. During the 12 calendar
months prior to, and including, the date of this prospectus supplement, we have not sold any securities pursuant to General Instruction
I.B.6 of Form S-3. As of the date of this prospectus supplement, the aggregate amount of securities we are permitted to sell pursuant
to General Instruction I.B.6 is $10,431,194. As a result of the limitations of General Instruction I.B.6, and in accordance with the terms
of the Equity Distribution Agreement, we are registering the offer and sale of shares of our common stock having an aggregate offering
price of up to $10,431,194 from time to time through JMP Securities LLC.
Our common stock is traded on the Nasdaq Capital
Market under the symbol “IDRA.” On March 30, 2022, the last reported sale price of our common stock was $0.5233 per share.
Investing in our common stock involves significant
risks. See “Risk Factors” in the Prospectus and in the documents incorporated by reference in this prospectus supplement and
the Prospectus for a discussion of the factors you should consider before deciding to purchase our common stock.
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus
supplement and accompanying prospectus. Any representation to the contrary is a criminal offense.
JMP Securities
A
CITIZENS COMPANY
The date of this prospectus supplement is March 31,
2022.
Idera Pharmaceuticals (NASDAQ:IDRA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024